Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | MAPT | P10636 | 1/20 | 0.42 |
| ▸ | GLA | P06280 | 1/20 | 0.37 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.37 |
| ▸ | MTNR1A | P48039 | 2/20 | 0.36 |
| ▸ | IDO1 | P14902 | 1/20 | 0.36 |
| ▸ | LMNA | P02545 | 1/20 | 0.36 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.36 |
| ▸ | CYP19A1 | P11511 | 1/20 | 0.35 |
| ▸ | TRPM8 | Q7Z2W7 | 1/20 | 0.35 |
| ▸ | HTT | P42858 | 1/20 | 0.35 |
| ▸ | ADAM10 | O14672 | 1/20 | 0.35 |
| ▸ | MMP1 | P03956 | 1/20 | 0.35 |
| ▸ | MMP2 | P08253 | 1/20 | 0.35 |
| ▸ | MMP9 | P14780 | 1/20 | 0.35 |
| ▸ | MMP14 | P50281 | 1/20 | 0.35 |
| ▸ | ADAM17 | P78536 | 1/20 | 0.35 |
| ▸ | KCNK3 | O14649 | 1/20 | 0.35 |
| ▸ | KCNA3 | P22001 | 1/20 | 0.35 |
| ▸ | KCNA5 | P22460 | 1/20 | 0.35 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL6663264 | 0.81 | LMNA (0.56) | L3MBTL1MAPTKMT2AIDO1LMNA | |
| SCHEMBL19628651 | 0.81 | MAPT (0.39) | MAPTKMT2AMTNR1AIDO1LMNA | |
| SCHEMBL17038779 | 0.70 | MTNR1B (0.42) | GLAKMT2AMTNR1AALDH1A1TAAR1 | |
| SCHEMBL10447512 | 0.70 | L3MBTL1 (0.59) | L3MBTL1MAPTGLAKMT2ALMNA | |
| SCHEMBL9331618 | 0.69 | L3MBTL1 (0.58) | L3MBTL1MAPTGLAKMT2ALMNA | |
| SCHEMBL19628875 | 0.69 | — | — | |
| SCHEMBL19628650 | 0.69 | ALDH1A1 (0.51) | L3MBTL1MAPTSMN1; SMN2CYP19A1HTT | |
| SCHEMBL7618103 | 0.69 | LTA4H (0.48) | EPHX2 | |
| SCHEMBL7618099 | 0.69 | LTA4H (0.48) | EPHX2 | |
| SCHEMBL9803524 | 0.69 | ACHE (0.38) | — |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 2 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200289554-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2020-09-17 | — | — | US | disclosed |
| WO-2017199028-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | THE UNIVERSITY COURT OF THE UNIVERSITY OF EDINBURGH (GB) | 2017-11-23 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20200289554-A1 | BIOORTHOGONAL COMPOUNDS COMPRISING A PROPARGYL GROUP FOR TREATING CANCER | MCL1, DNPEP, PPOX | L3MBTL1 1016/4885MAPT 3915/4885GLA 448/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.